Editorial comment.
Ryan
Christopher W
CW
Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, USA.
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects*; D000069448:Denosumab; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy; D053245:RANK Ligand / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab